{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:21:18Z","timestamp":1791933678821,"version":"4.3.4"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use primarily due to their weight-reduction effects, although a regulatory review was undertaken for potential suicidality concern.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate potential signals for suicidal and self-injurious adverse drug reactions (ADRs) associated with the GLP-1 RAs semaglutide and liraglutide.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Disproportionality analysis through the case-control design using the World Health Organization (WHO) global database of suspected ADRs. Participants were clinical patients worldwide experiencing an ADR suspectedly attributable to semaglutide or liraglutide in the database from inception to August 30, 2023. Data were analyzed from September to December 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Treatment with semaglutide or liraglutide regardless of indication or treatment duration.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Reporting odds ratio (ROR) and the bayesian information component (IC) with 95% CIs were calculated as measures of disproportionate reporting of suicidal and self-injurious ADRs associated with semaglutide and liraglutide compared with all other medications. Sensitivity analyses were conducted including patients with coreported use of antidepressants and benzodiazepines and using dapagliflozin, metformin, and orlistat as comparators. A disproportionality signal was considered when the lower limits of the ROR and IC were above 1 and 0, respectively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 107 (median [IQR] age 48 [40-56] years; 59 female patients [55%]) and 162 (median [IQR] age 47 [38-60] years; 100 female patients [61%]) cases of suicidal and\/or self-injurious ADRs were reported between November 2000 and August 2023 with semaglutide and liraglutide, respectively. Significant disproportionality was detected only for semaglutide-associated suicidal ideation (ROR, 1.45; 95% CI, 1.18-1.77; IC, 0.53; 95% CI, 0.19-0.78), which remained significant in patients with coreported use of antidepressants (ROR, 4.45; 95% CI, 2.52-7.86; IC, 1.96; 95% CI, 0.98-2.63) and benzodiazepines (ROR, 4.07; 95% CI, 1.69-9.82; IC, 1.67; 95% CI, 0.11-2.65), when compared with dapagliflozin (ROR, 5.56; 95% CI, 3.23-9.60; IC, 0.70; 95% CI, 0.36-0.95), metformin (ROR, 3.86; 95% CI, 2.91-5.12; IC, 1.20; 95% CI, 0.94-1.53) and orlistat (ROR, 4.24; 95% CI, 2.69-6.69; IC, 0.70; 95% CI, 0.36-0.95).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study using the WHO database found a signal of semaglutide-associated suicidal ideation, which warrants urgent clarification.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.23385","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T11:02:48Z","timestamp":1724151768000},"page":"e2423385","source":"Crossref","is-referenced-by-count":110,"title":["Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality"],"prefix":"10.1001","volume":"7","author":[{"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[{"name":"The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, New York"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, Glen Oaks, New York"},{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Weiler","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland"},{"name":"Institute of Primary Care, University of Zurich and University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gastaldon","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy"},{"name":"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"10026","key":"zoi240740r1","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19\u00b72 million participants.","volume":"387","author":"Collaboration","year":"2016","journal-title":"Lancet"},{"key":"zoi240740r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity.","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"issue":"9","key":"zoi240740r3","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2018-02685","article-title":"Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide.","volume":"104","author":"Fonseca","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"zoi240740r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US.","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"key":"zoi240740r8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/bmj.p1693","article-title":"UK clinics told to stop prescribing antidiabetes drugs for weight loss, after shortages.","volume":"382","author":"Iacobucci","year":"2023","journal-title":"BMJ"},{"key":"zoi240740r9","doi-asserted-by":"publisher","first-page":"k4880","DOI":"10.1136\/bmj.k4880","article-title":"Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.","volume":"363","author":"Abrahami","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"zoi240740r10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer.","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"11","key":"zoi240740r12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.2017.19.issue-11","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.","volume":"19","author":"O\u2019Neil","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"zoi240740r13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi240740r14","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/dom.2018.20.issue-9","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"zoi240740r15","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity.","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi240740r21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"zoi240740r22","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2023.2474","article-title":"Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.","volume":"66","author":"Chen","year":"2023","journal-title":"Eur Psychiatry"},{"issue":"2","key":"zoi240740r23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"zoi240740r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113168","article-title":"Safety of antipsychotic drugs: a systematic review of disproportionality analysis studies.","volume":"404","author":"Cepaityte","year":"2021","journal-title":"Behav Brain Res"},{"issue":"6","key":"zoi240740r25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems.","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"zoi240740r26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-022-01258-0","article-title":"Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: a scoping review of the global literature.","volume":"46","author":"Sartori","year":"2023","journal-title":"Drug Saf"},{"issue":"6","key":"zoi240740r28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"6","key":"zoi240740r29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): development and statement.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"5","key":"zoi240740r30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR database system: basic facts.","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"issue":"6","key":"zoi240740r34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23br14923","article-title":"Dual orexin receptor antagonists and suicide risk: findings from the WHO spontaneous reporting database.","volume":"84","author":"Salvo","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"zoi240740r35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.v11:1","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"zoi240740r36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"zoi240740r37","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820926000","article-title":"Effects of metformin in obesity treatment in different populations: a meta-analysis.","author":"Pu","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"zoi240740r38","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023.","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi240740r40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort.","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"zoi240740r41","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1097\/SLA.0000000000004232","article-title":"Risk factors for suicide after bariatric surgery in a population-based nationwide study in five Nordic countries.","volume":"275","author":"Kauppila","year":"2022","journal-title":"Ann Surg"},{"issue":"4","key":"zoi240740r42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.pcd.2010.07.002","article-title":"Correlates of depression among people with diabetes: the Translating Research Into Action for Diabetes (TRIAD) study.","volume":"4","author":"Waitzfelder","year":"2010","journal-title":"Prim Care Diabetes"},{"issue":"7","key":"zoi240740r43","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/ph16070994","article-title":"Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration\u2019s FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset.","volume":"16","author":"Chiappini","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"zoi240740r44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/soc.2014.40.issue-1","article-title":"Endogenous selection bias: the problem of conditioning on a collider variable.","volume":"40","author":"Elwert","year":"2014","journal-title":"Annu Rev Sociol"},{"key":"zoi240740r45","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.23-00318","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders.","author":"Bremmer","year":"2023","journal-title":"J Stud Alcohol Drugs"},{"key":"zoi240740r4","unstructured":"CBS News. Weight loss TikTok trend triggers shortage of diabetic medication. Accessed February 16, 2024. https:\/\/www.cbsnews.com\/baltimore\/news\/weight-loss-tiktok-trend-triggers-shortage-of-diabetic-medication\/"},{"key":"zoi240740r5","unstructured":"US Food and Drug Administration. FDA drug shortages. Accessed February 16, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/"},{"key":"zoi240740r7","unstructured":"Australian Goverment Department of Health and Aged Care Therapeutic Goods Administration. About the Ozempic (semaglutide) shortage 2022 and 2023. Accessed February 16, 2024. https:\/\/www.tga.gov.au\/safety\/shortages\/information-about-major-medicine-shortages\/about-ozempic-semaglutide-shortage-2022-and-2023"},{"key":"zoi240740r11","unstructured":"European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. Accessed September 4, 2023. https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists"},{"key":"zoi240740r16","unstructured":"European Medicines Agency. GLP-1 receptor agonists\u2019 review: PRAC requests further clarifications from marketing authorisation holders. Accessed February 16, 2024. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-november-2023"},{"key":"zoi240740r17","unstructured":"Reuters. UK probing novos ozembic weight loss drug saxenda over suicidal self-harming. Accessed September 4, 2023. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/uk-probing-novos-ozempic-weight-loss-drug-saxenda-over-suicidal-self-harming-2023-07-26\/"},{"key":"zoi240740r18","unstructured":"US Food and Drug Administration. Update on FDA\u2019s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Preliminary evaluation does not suggest a causal link. Accessed February 16, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type"},{"key":"zoi240740r19","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. Accessed May 19, 2024. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024"},{"key":"zoi240740r20","unstructured":"Youmshajekian? L. Evidence weighed for suicide\/self-harm with obesity drugs. Accessed September 4, 2023. https:\/\/www.medscape.com\/viewarticle\/994266?form=fpf"},{"key":"zoi240740r27","unstructured":"READUS-PV. The REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance. Accessed May 17, 2024. https:\/\/readus-statement.org\/"},{"key":"zoi240740r31","unstructured":"Uppsala Monitoring center. Accessed February 2021. https:\/\/who-umc.org\/vigibase\/"},{"key":"zoi240740r32","unstructured":"World Health Organization. ATC\/DDD index. Accessed January 20, 2024. https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"zoi240740r33","unstructured":"World Health Organization. MedDRA hierarchy. Accessed January 20, 2024. https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy"},{"key":"zoi240740r39","unstructured":"Novo Nordisk. WEGOVY (semaglutide) injection, for subcutaneous use. Accessed July 31, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s011lbl.pdf"},{"key":"zoi240740r46","unstructured":"US Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss. Accessed February 16, 2024. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss"},{"key":"zoi240740r47","unstructured":"Sample? I. UK public warned over dangers of fake weight loss medication pens. Pre-filled injection devices claimed to hold Ozempic or Saxenda may contain other substances, regulator says. The Guardian. Accessed August 11, 2023. https:\/\/www.theguardian.com\/society\/2023\/oct\/26\/uk-public-warned-over-dangers-of-fake-weight-loss-medication-pens"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822453\/schoretsanitis_2024_oi_240740_1723229508.10987.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T11:03:03Z","timestamp":1724151783000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.23385","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}